A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies – Beigene

⟵ Back to Search Results

A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies

Beigene Study ID

BGB-16673-101

ClinicalTrials.gov ID

NCT05006716

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents